Cold Plasmas for Biofilm Control: Opportunities and Challenges

Brendan F. Gilmore*, Padrig B. Flynn, Séamus O'Brien, Noreen Hickok, Theresa Freeman, Paula Bourke

*Corresponding author for this work

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Bacterial biofilm infections account for a major proportion of chronic and medical device associated infections in humans, yet our ability to control them is compromised by their inherent tolerance to antimicrobial agents. Cold atmospheric plasma (CAP) represents a promising therapeutic option. CAP treatment of microbial biofilms represents the convergence of two complex phenomena: the production of a chemically diverse mixture of reactive species and intermediates, and their interaction with a heterogeneous 3D interface created by the biofilm extracellular polymeric matrix. Therefore, understanding these interactions and physiological responses to CAP exposure are central to effective management of infectious biofilms. We review the unique opportunities and challenges for translating CAP to the management of biofilms.

Original languageEnglish
Pages (from-to)627-638
JournalTrends in Biotechnology
Volume36
Issue number6
Early online date02 May 2018
DOIs
Publication statusPublished - 01 Jun 2018

Fingerprint

Plasma Gases
Biofilms
Plasmas
Antimicrobial agents
Beam plasma interactions
Anti-Infective Agents
Bacterial Infections
Extracellular Matrix
Equipment and Supplies
Infection

Cite this

@article{c5510bca34bc432a9824c32a54354204,
title = "Cold Plasmas for Biofilm Control: Opportunities and Challenges",
abstract = "Bacterial biofilm infections account for a major proportion of chronic and medical device associated infections in humans, yet our ability to control them is compromised by their inherent tolerance to antimicrobial agents. Cold atmospheric plasma (CAP) represents a promising therapeutic option. CAP treatment of microbial biofilms represents the convergence of two complex phenomena: the production of a chemically diverse mixture of reactive species and intermediates, and their interaction with a heterogeneous 3D interface created by the biofilm extracellular polymeric matrix. Therefore, understanding these interactions and physiological responses to CAP exposure are central to effective management of infectious biofilms. We review the unique opportunities and challenges for translating CAP to the management of biofilms.",
author = "Gilmore, {Brendan F.} and Flynn, {Padrig B.} and S{\'e}amus O'Brien and Noreen Hickok and Theresa Freeman and Paula Bourke",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.tibtech.2018.03.007",
language = "English",
volume = "36",
pages = "627--638",
journal = "Trends in Biotechnology",
issn = "0167-7799",
publisher = "Elsevier Limited",
number = "6",

}

Cold Plasmas for Biofilm Control : Opportunities and Challenges. / Gilmore, Brendan F.; Flynn, Padrig B.; O'Brien, Séamus; Hickok, Noreen; Freeman, Theresa; Bourke, Paula.

In: Trends in Biotechnology, Vol. 36, No. 6, 01.06.2018, p. 627-638.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cold Plasmas for Biofilm Control

T2 - Opportunities and Challenges

AU - Gilmore, Brendan F.

AU - Flynn, Padrig B.

AU - O'Brien, Séamus

AU - Hickok, Noreen

AU - Freeman, Theresa

AU - Bourke, Paula

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Bacterial biofilm infections account for a major proportion of chronic and medical device associated infections in humans, yet our ability to control them is compromised by their inherent tolerance to antimicrobial agents. Cold atmospheric plasma (CAP) represents a promising therapeutic option. CAP treatment of microbial biofilms represents the convergence of two complex phenomena: the production of a chemically diverse mixture of reactive species and intermediates, and their interaction with a heterogeneous 3D interface created by the biofilm extracellular polymeric matrix. Therefore, understanding these interactions and physiological responses to CAP exposure are central to effective management of infectious biofilms. We review the unique opportunities and challenges for translating CAP to the management of biofilms.

AB - Bacterial biofilm infections account for a major proportion of chronic and medical device associated infections in humans, yet our ability to control them is compromised by their inherent tolerance to antimicrobial agents. Cold atmospheric plasma (CAP) represents a promising therapeutic option. CAP treatment of microbial biofilms represents the convergence of two complex phenomena: the production of a chemically diverse mixture of reactive species and intermediates, and their interaction with a heterogeneous 3D interface created by the biofilm extracellular polymeric matrix. Therefore, understanding these interactions and physiological responses to CAP exposure are central to effective management of infectious biofilms. We review the unique opportunities and challenges for translating CAP to the management of biofilms.

UR - http://www.scopus.com/inward/record.url?scp=85046651727&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2018.03.007

DO - 10.1016/j.tibtech.2018.03.007

M3 - Review article

C2 - 29729997

AN - SCOPUS:85046651727

VL - 36

SP - 627

EP - 638

JO - Trends in Biotechnology

JF - Trends in Biotechnology

SN - 0167-7799

IS - 6

ER -